The Fishwick/Johnson group is a medicinal chemistry research group based in the School of Chemistry at the University of Leeds. We use computational methods to guide synthesis of potential drugs for a variety of therapeutic areas including the development of antibacterial, antimalarial, antithrombotic, anti-Alzheimer’s and anti-cancer agents. Read more about our work to combat antimicrobial resistance here.
The group utilises a range of computational tools in designing potential drugs including the de novo design software SPROUT. Molecular docking software such as ehits and AutoDock is available to help assess the potential of designed scaffolds or to perform vHTS. Once potential drug compounds have been synthesised they are sent to collaborators, within the University of Leeds or externally, for biological assay.
Projects within the group involve collaboration with other Universities in the UK and abroad and with the pharmaceutical industry. Funding has been provided by a range of funding bodies including the BBSRC, EPSRC, MRC, ERC, Welcome Trust, British Heart Foundation and the NIH.